Blanca Scheijen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1451407/publications.pdf

Version: 2024-02-01

57	2,042	331538	243529
papers	citations	21 h-index	44 g-index

58	58	58	4127
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements. Modern Pathology, 2022, 35, 757-766.	2.9	11
2	IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Advances, 2022, 6, 2254-2266.	2.5	7
3	Next-Generation Sequencing-Based Clonality Detection of Immunoglobulin Gene Rearrangements in B-Cell Lymphoma. Methods in Molecular Biology, 2022, , 7-42.	0.4	8
4	Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma. Cancers, 2022, 14, 3222.	1.7	5
5	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. Leukemia, 2021, 35, 924-928.	3.3	3
6	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. Clinical Chemistry, 2021, 67, 867-875.	1.5	12
7	Next-Generation Sequencingâ€“Based Clonality Assessment of Ig Gene Rearrangements. Journal of Molecular Diagnostics, 2021, 23, 1105-1115.	1.2	25
8	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers, 2020, 12, 3553.	1.7	22
9	Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. Cancers, 2020, 12, 3052.	1.7	13
10	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood, 2019, 134, 946-950.	0.6	18
11	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia, 2019, 33, 2241-2253.	3.3	177
12	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia, 2019, 33, 2254-2265.	3.3	70
13	Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia, 2019, 33, 2227-2240.	3.3	92
14	Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes. Diagnostic Pathology, 2019, 14, 15.	0.9	9
15	Tumor suppressors BTG1 and BTG2: Beyond growth control. Journal of Cellular Physiology, 2019, 234, 5379-5389.	2.0	149
16	Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. , 2019, 2, 647-664.		9
17	Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1. Experimental Hematology, 2018, 60, 57-62.e3.	0.2	4
18	Multifocal occurrence of extra-abdominal desmoid type fibromatosis â€“ A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case. Annals of Diagnostic Pathology, 2018, 35, 38-41.	0.6	6

#	Article	IF	Citations
19	The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2018, 103, 565-574.	1.7	113
20	Glucocorticoid Resistance in IKZF1-Deleted BCP-ALL: It Is PTEN Again. Blood, 2018, 132, 4088-4088.	0.6	0
21	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology, 2017, 18, 694-704.	7.0	67
22	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica, 2017, 102, 541-551.	1.7	49
23	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. Journal of Hematopathology, 2017, 10, 91-107.	0.2	45
24	Pathways towards indolent B-cell lymphoma â€" Etiology and therapeutic strategies. Blood Reviews, 2017, 31, 426-435.	2.8	7
25	Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development. Haematologica, 2016, 101, e272-e276.	1.7	24
26	Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress. Oncotarget, 2016, 7, 3128-3143.	0.8	29
27	Altered cerebellum development and impaired motor coordination in mice lacking the Btg1 gene: Involvement of cyclin D1. Developmental Biology, 2015, 408, 109-125.	0.9	28
28	Targeted Locus Amplification & Next Generation Sequencing for the Detection of Recurrent and Novel Gene Fusions for Improved Treatment Decisions in Pediatric Acute Lymphoblastic Leukemia. Blood, 2015, 126, 696-696.	0.6	3
29	Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton. PLoS ONE, 2015, 10, e0131481.	1.1	11
30	Tumor Suppressors BTG1 and IKZF1 Cooperate during Mouse Leukemia Development and Impact Relapse Rate in Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 905-905.	0.6	4
31	<scp>DNA</scp> copy number alterations mark disease progression in paediatric chronic myeloid leukaemia. British Journal of Haematology, 2014, 166, 250-253.	1.2	9
32	The Leukemia-Associated Protein BTG1 Is Required for ATF4-Mediated Cellular Stress Responses. Blood, 2014, 124, 3587-3587.	0.6	3
33	Btg1-Deficiency Promotes ETV6-RUNX1-Mediated Leukemic Transformation By Upregulation of BCL6. Blood, 2014, 124, 5193-5193.	0.6	0
34	Tumor Suppressors Btg1 and Btg2 Regulate B Lineage Commitment through Modulation of Ebf1 Activity. Blood, 2014, 124, 4311-4311.	0.6	0
35	Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. PLoS Genetics, 2013, 9, e1003225.	1.5	323
36	Loss Of Tumor Suppressor BTG1 Enhances ATF4 Function and Promotes Cell Survival. Blood, 2013, 122, 3796-3796.	0.6	0

#	Article	IF	Citations
37	Loss Of BTG1 Function Promotes ETV6-RUNX1-Mediated Leukemic Transformation. Blood, 2013, 122, 2545-2545.	0.6	0
38	P190BCR-ABL1 Signaling Modulates The Function Of Tumor Suppressor Protein IKZF1. Blood, 2013, 122, 3809-3809.	0.6	0
39	Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1313-1313.	0.6	0
40	Loss Of IKZF1 Function Mediates Resistance Towards Glucocorticoid-Induced Apoptosis. Blood, 2013, 122, 3865-3865.	0.6	0
41	B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Specific Copy Number Alterations Are Unique For Progressive Pediatric Chronic Myeloid Leukemia (CML): A Large Cohort Study. Blood, 2013, 122, 2715-2715.	0.6	0
42	The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution. PLoS Genetics, 2012, 8, e1002533.	1.5	75
43	Tumor Suppressors BTG1 and BTG2 Fulfill Both Unique and Overlapping Functions During Normal B Lymphocyte Development. Blood, 2012, 120, 1303-1303.	0.6	0
44	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research, 2011, 13, R82.	2.2	74
45	Focal BTG1 Deletions Occur in Specific Precursor B-Cell Acute Lymphoblastic Leukemia Subtypes At Defined Hotspots Due to Aberrant V(D)J Recombination. Blood, 2011, 118, 399-399.	0.6	2
46	BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood, 2010, 115, 4810-4819.	0.6	69
47	BTG1, a Gene Frequently Deleted in Pre-B ALL, Controls Glucocorticoid Receptor-Mediated Gene Expression.. Blood, 2009, 114, 3458-3458.	0.6	0
48	Deletion of IKZF1 in Pediatric Precursor-B ALL Is a Strong Prognostic Marker for Relapse.. Blood, 2009, 114, 1104-1104.	0.6	1
49	Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia. , 2006, , 93-113.		1
50	FOXO Transcription Factors Are Negatively Regulated by p38 Map Kinases Downstream of FLT3 Receptor Signaling.. Blood, 2005, 106, 203-203.	0.6	1
51	High Incidence of Thymic Epithelial Tumors in E2F2 Transgenic Mice. Journal of Biological Chemistry, 2004, 279, 10476-10483.	1.6	31
52	FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene, 2004, 23, 3338-3349.	2.6	108
53	NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood, 2004, 103, 4622-4629.	0.6	84
54	Constitutive E2F1 Overexpression Delays Endochondral Bone Formation by Inhibiting Chondrocyte Differentiation. Molecular and Cellular Biology, 2003, 23, 3656-3668.	1.1	40

#	Article	IF	Citations
55	Mutated Tyrosine Kinases As Therapeutic Targets In Myeloid Leukemias. Advances in Experimental Medicine and Biology, 2003, 532, 121-140.	0.8	27
56	Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene, 2002, 21, 3314-3333.	2.6	164
57	Identification and Characterization of Collaborating Oncogenes in Compound Mutant Mice. , 1998, , 15-30.		8